// App-Quantinova.ai

3072 : Preliminary interim results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic (Pb-Tx) CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors.

Researchers

Presenter

  • Rachel E. Sanborn

Principal Investigators

  • Catharina Wilhelmina Menke

  • Karen A. Autio

  • Hendrik-Tobias Arkenau

  • Javier Garcia Corbacho

  • Patricia Lo Russo

  • Elizabeth Ruth Plummer

  • Nataliya Volodymyrivna Uboha

  • Morganna Louise Freeman

  • Jerzy Wydmanski

  • Vanessa Huels

  • Beiyao Zheng

  • Matthias Will

  • Rachel W. Humphrey

  • Fiona Thistlethwaite

  • Elisabeth G.E. de Vries

  • Anthony B. El-Khoueiry

Medical Centers

  • Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, OR

  • Cancer Center Amsterdam, Amsterdam, Netherlands

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Sarah Cannon Research Institute, London, United Kingdom

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Yale University School of Medicine and Yale Cancer Center, New Haven, CT

  • Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom

  • University of Wisconsin Comprehensive Cancer Center, Madison, WI

  • The Angeles Clinic and Research Institute, Los Angeles, CA

  • NZOZ Vegamed, Katowice, Poland

  • CytomX Therapeutics, South San Francisco, CA

  • The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom

  • Universitair Medisch Centrum Groningen, Groningen, Netherlands

  • University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

Locations

  • Netherlands

  • Poland

  • Spain

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Cytotoxic T-lymphocyte-associated protein 4

Drug/Treatment

  • Ipilimumab

Outcome

  • Unknown

Study Design

  • First-In-Human

Phase

  • I/II

Study Id's

  • NCT03013491

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved